Marc Pelletier
Company: Novartis AG
Job title: Translational Immune Oncology, Associate Director
Seminars:
Targeting NLRP3 in Myelodysplastic Syndrome: Initial Results from Phase Ib Trial of DFV890 9:00 am
day: Conference Day One AM